Trial
NCT04277546
Open-label Extension Study of Brazikumab in Ulcerative Colitis
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
AstraZeneca
Collaborators
—
Condition
Ulcerative Colitis
Intervention
Brazikumab Maintenance Dose
Why stopped
Strategic decision to discontinue the development of brazikumab in inflammatory bowel disease.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-23